Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
Articles by Marisa Wexler, MS
As part of its Path to a Cure initiative, the Cystic Fibrosis Foundation announced three new awards to fund…
Children in the U.S. with cystic fibrosis (CF) tend to have better lung function than young people with the disease…
Vertex Pharmaceuticals has made a $32 million purchase from Concert Pharmaceuticals related to future milestones from the 2017…
Combining AzurRx BioPharma‘s investigational therapy MS1819 with standard pancreatic enzyme replacement therapy (PERT) can improve fat absorption in cystic fibrosis…
People with cystic fibrosis (CF) experience many barriers that limit their participation in physical activity, ranging from a lack…
The European Commission (EC) agreed to expand use of Vertex’s Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to…
Blocking an enzyme called phosphodiesterase-4 (PDE4) may be useful in the treatment of dry mouth and cystic fibrosis (CF),…
A European Medicines Agency (EMA) committee favors extending the label for Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat cystic…
Bronchitol (mannitol), an inhaled mucus-clearing treatment for cystic fibrosis (CF), is now commercially available in the U.S., according…